New Alzheimer’s disease diagnostics and psychological clinical perspectives

The landscape of Alzheimer’s disease (AD) management is undergoing a profound paradigm shift. Driven by breakthroughs in blood-based biomarkers (BBMs) such as plasma phosphorylated tau 217 (p-tau217), clinicians can now identify biological risk factors at preclinical and presymptomatic stages with high accuracy and minimal invasiveness. Yet, despite these monumental diagnostic strides, healthcare systems globally face a critical vulnerability: psychological clinical services have failed to expand in tandem. A recently published theoretical perspective paper in Frontiers in Psychology sheds light on this discrepancy, arguing that integrating mental health professionals into multidisciplinary dementia care is no longer optional—it is a public health imperative. Authored by M. T. M. Aversi, P. M. Freitas, and T. A. Aversi-Ferreira, the paper outlines a comprehensive, three-phase roadmap to bridge the gap between biological risk identification and psychological support.

Evolution of Alzheimer’s Diagnosis: From Syndromes to Biomarkers

For over a century, since German psychiatrist Alois Alzheimer first examined the neuropathological hallmarks of Auguste Deter in 1906, diagnosing AD relied primarily on clinical observations, progressive cognitive decline, and exclusionary testing. Definitive confirmation traditionally required post-mortem autopsies. Over the past two decades, however, neuroimaging modalities like amyloid and tau positron emission tomography (PET) and cerebrospinal fluid (CSF) assays revolutionized the field.

Despite their precision, PET and CSF methods require specialized infrastructure, expensive radiotracers, or invasive lumbar punctures, largely restricting them to tertiary academic centers. The emergence of blood-based biomarkers—most notably plasma p-tau217—has democratized the diagnostic process. Requiring only a routine venous blood draw, p-tau217 achieves pooled sensitivities and specificities between 82% and 86% (with some estimates reaching 90%), offering a scalable tool for population-level risk assessment.

This technological leap sparked a fierce debate within the scientific community regarding diagnostic terminology and ethics. The 2024 Revised Criteria for Diagnosis and Staging by the National Institute on Aging–Alzheimer’s Association (NIA-AA) classify biomarker-positive, cognitively unimpaired individuals as being in the early biological stage of AD. Conversely, the International Working Group (IWG) advocates for a more conservative clinical-biological approach. The IWG argues that cognitively normal individuals with positive biomarkers should be designated as "at risk" rather than formally diagnosed with AD. From a psychological standpoint, the IWG framework is heavily favored: labeling healthy individuals with a fatal neurodegenerative disease years or decades before symptoms appear risks inducing severe iatrogenic anxiety, depressive symptoms, and identity disruption.

The Global Burden and the Case for Lifelong Prevention

The urgency of reforming dementia care is underscored by staggering demographic trends. According to the Alzheimer’s Association, an estimated 6.9 million Americans aged 65 and older were living with Alzheimer’s dementia in 2024, with total care costs projected to near $1 trillion by 2050. Globally, Alzheimer’s Disease International reported more than 55 million people living with dementia in 2020—a figure expected to surge to 78 million by 2030 and 139 million by 2050, with low- and middle-income countries (LMICs) experiencing the fastest growth.

Simultaneously, the landmark 2024 Lancet Commission on dementia prevention estimated that up to 45% of worldwide dementia cases could be prevented or delayed by addressing 14 modifiable risk factors across the lifespan. Many of these factors—such as depression, social isolation, chronic stress, and cognitive inactivity—fall squarely within the domain of psychological clinical practice.

However, experts caution against overstating psychology’s reach. While mental health interventions effectively treat depression and encourage behavioral change, other critical risk factors like hypertension, diabetes, midlife obesity, hearing loss, air pollution, and traumatic brain injury require pharmacological, surgical, audiological, or environmental interventions. Psychology’s core contribution lies in patient adherence, behavioral modification, and cognitive reserve enhancement.

A Proposed Three-Phase Roadmap for Psychological Integration

To operationalize these insights, Aversi and colleagues propose a structured, three-phase roadmap designed to embed psychological care seamlessly into multidisciplinary healthcare systems.

Phase 1: Universal Prevention

Targeting the general population from early life onward, Phase 1 focuses on health promotion and primary prevention. Interventions include school-based emotional education, public psychoeducation campaigns, and community programs aimed at building cognitive reserve. Digital health tools, such as telepsychology and mobile applications, offer a scalable and cost-effective mechanism to deliver psychoeducation and remote cognitive stimulation, overcoming geographic barriers especially relevant in resource-limited regions.

Phase 2: Targeted Prevention for At-Risk Individuals

Triggered by elevated biomarker profiles (such as positive p-tau217 assays) or clinical risk observations, Phase 2 centers on individuals who remain cognitively unimpaired. This phase requires rigorous neuropsychological evaluation—utilizing sensitive instruments like the Preclinical Alzheimer Cognitive Composite (PACC)—paired with structured, counselor-assisted risk disclosure protocols. Recognizing that biomarker disclosure can evoke acute anxiety or social withdrawal, psychologists must provide pre-test counseling, supported result disclosure, and continuous emotional monitoring. Furthermore, this phase extends support to family members and informal caregivers who frequently suffer from "pre-caregiving stress" and anticipatory grief.

Phase 3: Intervention for Diagnosed AD

When clinical symptoms manifest and formal diagnosis occurs, Phase 3 pivots toward established clinical management. Psychologists deploy cognitive rehabilitation—a behavioral therapy designed to optimize remaining functioning and enhance the quality of life for patients. Simultaneously, this phase prioritizes structured psychological support, psychoeducation, and burden-reduction strategies for primary caregivers, whose physical and emotional strain remains a major determinant of care quality and sustainability.

Professional, Ethical, and Policy Implications

Implementing this roadmap exposes significant structural bottlenecks. Healthcare systems globally—particularly in LMICs—suffer from a severe shortage of psychologists integrated into neurology and geriatric teams. Furthermore, academic psychology training programs rarely prepare professionals for pre-dementia preventive roles or standardized risk disclosure counseling.

To overcome these barriers, the authors urge governments to revise public health policies to formally incorporate psychologists into primary, secondary, and tertiary care teams. At the primary care level, psychologists can provide matrix support to family health teams; at secondary and tertiary levels, they contribute to specialized diagnostics, neuropsychological assessment, and consultation-liaison services. Additionally, health systems must establish rigorous ethical frameworks for dynamic, staged informed consent regarding biomarker testing, ensuring that patients retain the autonomy to decide whether they wish to learn their biological risk status.

Ultimately, the integration of psychological clinical practice into modern Alzheimer’s diagnostics marks a crucial evolution toward person-centered, humane healthcare. By combining cutting-edge biomarkers with proactive mental health strategies, healthcare systems can shift from crisis management to lifelong brain health preservation, alleviating immense human and economic tolls worldwide.